Company intelligence / Profile preview
BioXL
Ramat Gan, Tel Aviv District, Israelbioxl.us ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BioXL develops innovative biopharmaceutical and diagnostic solutions targeting critical unmet medical needs, including a biologic therapy for pancreatic cancer ("CeaseCancer"), a rapid breast cancer risk prediction test ("CancerPredict"), and a combination treatment aimed at preventing progression from MCI to dementia ("NES‑Pharma"). Clinical results have not been published publicly.
- Therapeutic areas
- NeurologyOncology
- Modalities
- BiologicDiagnostic test
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Member of ARC Innovation at Sheba Medical Center
Beyond the preview
Go deeper on BioXL.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioXL.